140201-08-7 Usage
Chemical compound
Derived from the alkaloid trigonelline
Natural source
Found in various plants including fenugreek and coffee
Solubility
Water-soluble
Stability
Stable compound
Health benefits
Researched for potential health benefits
Antioxidant properties
Possesses antioxidant properties
Anti-diabetic effects
Linked to potential anti-diabetic effects
Anti-inflammatory effects
Linked to potential anti-inflammatory effects
Neuroprotective properties
Being investigated for potential neuroprotective properties
Mental health
Being investigated for its role in improving mental health
Field of interest
Natural compounds and their potential health benefits
Check Digit Verification of cas no
The CAS Registry Mumber 140201-08-7 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,4,0,2,0 and 1 respectively; the second part has 2 digits, 0 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 140201-08:
(8*1)+(7*4)+(6*0)+(5*2)+(4*0)+(3*1)+(2*0)+(1*8)=57
57 % 10 = 7
So 140201-08-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H9NO2/c1-8-4-2-3-6(5-8)7(9)10/h2,4-5H,3H2,1H3,(H,9,10)
140201-08-7Relevant articles and documents
NOVEL DRUGS FOR DEMENTIA
-
Example 3, (2008/06/13)
The invention is directed to compounds that are prodrugs containing a chemical delivery system (CDS) moiety and a cysteine protease inhibitor moiety. The CDS moiety targets the prodrug to the brain or central nervous system. The cysteine protease inhibitor inhibits cysteine proteases upon release from the prodrug. Cysteine protease inhibitors are effective for treating dementia, Alzheimer's disease and vascular dementia. Targeting the brain or central nervous system offers significant advantages in treating these conditions and diseases. A preferred CDS prodrug is a dihydrotrigoneline CDS moiety coupled to an epoxysuccinyl peptide cysteine protease inhibitor moiety.
